FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

BiondVax releases promising Ph2 universal flu vax results

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


BiondVax Pharmaceuticals has completed its first Phase II trial of Multimeric-001, its universal flu vaccine, and the results have spurred the company to begin planning its next test of the vaccine. The 200-participant study hit its primary and secondary endpoints, with good immunogenicity and safety data, including statistically significant antibody and cell-mediated immune responses.

"We have confirmed, in what is to our knowledge the first Phase II study of a universal influenza vaccine ever conducted in the world, that the Multimeric-001 vaccine is not only safe and immunogenic on its own, but it also has the potential to enhance the performance of traditional strain-dependant flu vaccines," Ron Babecoff, BiondVax's CEO, said in a release.

The Israeli company also stated that Multimeric-001, which was given in two doses during the trial, enhanced a traditional flu vaccine's performance. BiondVax's next trial of the vaccine is planned for the fourth quarter of this year and will evaluate the effects of the shot in elderly patients.

- check out the BiondVax release
- here's more from Reuters

Related Articles:
BiondVax looks to make mark in universal flu vax space
Fauci outlines R&D challenges to universal flu vaccine

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about flu vaccine   universal flu vaccine   BiondVax Pharmaceuticals